Results of the European survey on the assessment of deep molecular response in chronic phase CML patients during tyrosine kinase inhibitor therapy (EUREKA registry)
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023736%3A_____%2F19%3A00012723" target="_blank" >RIV/00023736:_____/19:00012723 - isvavai.cz</a>
Alternative codes found
RIV/00216224:14110/19:00111759 RIV/65269705:_____/19:00070858
Result on the web
<a href="https://doi.org/10.1007/s00432-019-02910-6" target="_blank" >https://doi.org/10.1007/s00432-019-02910-6</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1007/s00432-019-02910-6" target="_blank" >10.1007/s00432-019-02910-6</a>
Alternative languages
Result language
angličtina
Original language name
Results of the European survey on the assessment of deep molecular response in chronic phase CML patients during tyrosine kinase inhibitor therapy (EUREKA registry)
Original language description
The advent of tyrosine kinase inhibitor (TKI) therapies has revolutionized the treatment of chronic myeloid leukemia (CML). The European LeukemiaNet (ELN) recommends quantification of BCR–ABL1 transcripts by real-time quantitative PCR every 3 months during TKI treatment. Since a proportion of patients in deep molecular response (DMR: MR 4 , MR 4.5 , MR 5 ) maintain remission after treatment stop, assessment of DMR is crucial. However, systematically collected molecular data, monitored with sensitive standardized assays, are not available outside clinical trials. Data were collected on the standardized assessment of molecular response in the context of real-life practice. BCR–ABL1 transcript levels after > 2 years of TKI therapy were evaluated for DMR by local laboratories as well as standardized EUTOS laboratories. Since standardized molecular monitoring is a prerequisite for treatment discontinuation, central surveillance of the performance of the participating laboratories was carried out
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30502 - Other medical science
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2019
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Journal of cancer research and clinical oncology
ISSN
0171-5216
e-ISSN
—
Volume of the periodical
145
Issue of the periodical within the volume
6
Country of publishing house
DE - GERMANY
Number of pages
6
Pages from-to
1645-1650
UT code for WoS article
000468537100023
EID of the result in the Scopus database
2-s2.0-85064279744